Rocket


News + Filings
Transactions





All
All (ex-4s)
10-K
10-Q
8-K
3,4,5
Proxy
Prospectus
Other


Schilke Tobin Create: Alert

All | News | Filings
Date FiledTypeDescription
08/15/2023 4 Schilke Tobin (CFO) has filed a Form 4 on Revance Therapeutics, Inc.
Txns: Granted 22,620 shares @ $0
Paid exercise price by delivering 11,215 shares @ $18.91, valued at $212.1k
07/05/2023 4 Schilke Tobin (CFO) has filed a Form 4 on Revance Therapeutics, Inc.
Txns: Granted 769 shares @ $15.606, valued at $12k
Sold 1,701 shares @ $25.04, valued at $42.6k
07/03/2023 144 Form 144 - Report of proposed sale of securities:
06/05/2023 4 Schilke Tobin (CFO) has filed a Form 4 on Revance Therapeutics, Inc.
Txns: Sold 2,701 shares @ $30.57, valued at $82.6k
Sold 500 shares @ $31, valued at $15.5k
06/02/2023 144 Form 144 - Report of proposed sale of securities:
06/01/2023 144 Form 144 - Report of proposed sale of securities:
05/16/2023 4 Schilke Tobin (CFO) has filed a Form 4 on Revance Therapeutics, Inc.
Txns: Granted 42,349 shares @ $0
Sold 21,401 shares @ $34.5469, valued at $739.3k
05/12/2023 144 Form 144 - Report of proposed sale of securities:
05/01/2023 144 Form 144 - Report of proposed sale of securities:
04/04/2023 4 Schilke Tobin (CFO) has filed a Form 4 on Revance Therapeutics, Inc.
Txns: Sold 3,201 shares @ $32.15, valued at $102.9k
03/17/2023 4 Schilke Tobin (CFO) has filed a Form 4 on Revance Therapeutics, Inc.
Txns: Paid exercise price by delivering 3,739 shares @ $30.65, valued at $114.6k
03/09/2023 4 Schilke Tobin (CFO) has filed a Form 4 on Revance Therapeutics, Inc.
Txns: Granted 42,349 shares @ $0
Sold 18,517 shares @ $31.5863, valued at $584.9k
03/08/2023 144 Form 144 - Report of proposed sale of securities:
03/02/2023 4 Schilke Tobin (CFO) has filed a Form 4 on Revance Therapeutics, Inc.
Txns: Sold 3,201 shares @ $33.5, valued at $107.2k
02/02/2023 4 Form 4 - Statement of changes in beneficial ownership of securities:
01/23/2023 4 Schilke Tobin (CFO) has filed a Form 4 on Revance Therapeutics, Inc.
Txns: Sold 1,000 shares @ $31, valued at $31k
01/10/2023 4 Schilke Tobin (CFO) has filed a Form 4 on Revance Therapeutics, Inc.
Txns: Sold 1,701 shares @ $25, valued at $42.5k
Sold 1,000 shares @ $28, valued at $28k
Sold 1,000 shares @ $30, valued at $30k
01/03/2023 4 Schilke Tobin (CFO) has filed a Form 4 on Revance Therapeutics, Inc.
Txns: Granted 645 shares @ $12.1805, valued at $7.9k
12/16/2022 4 Schilke Tobin (CFO) has filed a Form 4 on Revance Therapeutics, Inc.
Txns: Paid exercise price by delivering 1,557 shares @ $21.5, valued at $33.5k
07/05/2022 4 Form 4 - Statement of changes in beneficial ownership of securities:
03/17/2022 4 Form 4 - Statement of changes in beneficial ownership of securities:
02/17/2022 4 Schilke Tobin (CFO) has filed a Form 4 on Revance Therapeutics, Inc.
Txns: Paid exercise price by delivering 2,241 shares @ $13.35, valued at $29.9k
Paid exercise price by delivering 683 shares @ $13.35, valued at $9.1k
02/04/2022 4 Form 4 - Statement of changes in beneficial ownership of securities:
01/04/2022 4 Schilke Tobin (CFO) has filed a Form 4 on Revance Therapeutics, Inc.
Txns: Acquired 404 shares @ $13.872, valued at $5.6k
12/17/2021 4 Form 4 - Statement of changes in beneficial ownership of securities:
07/02/2021 4 Form 4 - Statement of changes in beneficial ownership of securities:
02/19/2021 4 Form 4 - Statement of changes in beneficial ownership of securities:
02/04/2021 4 Form 4 - Statement of changes in beneficial ownership of securities:
01/04/2021 4 Form 4 - Statement of changes in beneficial ownership of securities:
12/22/2020 4 Schilke Tobin (CFO) has filed a Form 4 on Revance Therapeutics, Inc.
Txns: Paid exercise price by delivering 1,556 shares @ $26.75, valued at $41.6k
10/02/2020 4 Form 4 - Statement of changes in beneficial ownership of securities:
07/02/2020 4 Form 4 - Statement of changes in beneficial ownership of securities:
02/19/2020 4 Form 4 - Statement of changes in beneficial ownership of securities:
01/24/2020 4 Schilke Tobin (CFO) has filed a Form 4 on Revance Therapeutics, Inc.
Txns: Granted 16,500 shares @ $0
Granted 97,500 options to buy @ $22.32, valued at $2.2M
  Next >>

Rocket Data Systems, Inc. © 2019 | Contact Us | Data Disclaimer | Terms of Use | Privacy